Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients.
Lymphovascular invasion represents a superior prognostic and predictive pathological factor of the duration of adjuvant chemotherapy for stage III colon cancer patients.
复制标题
DOI：
10.1186/s12885-022-10416-7
复制
发表时间：
2023-01-03
期刊：
影响因子：
3.8
通讯作者：
中科院分区：
文献类型：
--
作者：
血管浸润（LVI）和神经浸润（PNI）可能表明结直肠癌的生存结局较差，但很少有研究关注III期结肠癌。目前的研究旨在确认LVI和PNI的预后价值，并根据这两个病理因素确定可以从完整的辅助化疗中获益的患者。我们连续招募了402例III期结肠癌患者，这些患者于2007年11月至2016年6月在中山大学肿瘤防治中心接受结肠肿瘤切除术。生存分析采用Kaplan-Meier法和对数秩检验。通过考克斯比例风险分析确定与无病生存期（DFS）和总生存期（OS）相关的危险因素。141例（35.1%）患者出现LVI，108例（26.9%）患者出现PNI。与LV I阴性组相比，LV I阳性组的3年DFS（86.5% vs. 76.3%，P = 0.001）和OS（96.0% vs. 89.1%，P = 0.003）率较差。PNI阳性组3年无病生存率（72.5%）明显低于PNI阴性组（86.7%，P < 0.001）。完成6-8个周期辅助化疗的患者中，LVI阳性组的3年无病生存率（DFS）和总生存率（OS）均优于< 6个周期者（3年DFS：80.0%vs.64.9%，P = 0.019; 3年OS：93.2%vs.76.3%，P = 0.002）。在接受根治性治疗的III期结肠癌患者中，LVI是一个优于PNI的上级预后因素。PNI状态仅能预测3年无病生存率，不影响3年OS，LVI也是辅助化疗持续时间的有效指标。
Lymphovascular invasion (LVI) and perineural invasion (PNI) can indicate poor survival outcomes in colorectal cancer, but few studies have focused on stage III colon cancer. The current study aimed to confirm the prognostic value of LVI and PNI and identify patients who could benefit from a complete duration of adjuvant chemotherapy based on the two pathological factors. We enrolled 402 consecutive patients with stage III colon cancer who received colon tumor resection from November 2007 to June 2016 at Sun Yat-sen University Cancer Center. Survival analyses were performed by using Kaplan–Meier method with log-rank tests. Risk factors related to disease-free survival (DFS) and overall survival (OS) were identified through Cox proportional hazards analysis. 141 (35.1%) patients presented with LVI, and 108 (26.9%) patients with PNI. The LVI-positive group was associated with poorer 3-year DFS (86.5% vs. 76.3%, P = 0.001) and OS (96.0% vs. 89.1%, P = 0.003) rates compared with the LVI-negative group. The PNI-positive group showed a worse outcome compared with the PNI-negative group in 3-year DFS rate (72.5% vs. 86.7%, P < 0.001). Moreover, LVI-positive group present better 3-year DFS and OS rate in patients completing 6–8 cycles of adjuvant chemotherapy than those less than 6 cycles (3-year DFS: 80.0% vs. 64.9%, P = 0.019; 3-year OS: 93.2% vs. 76.3%, P = 0.002). LVI is a superior prognostic factor to PNI in stage III colon cancer patients undergoing curative treatment. PNI status can noly predict the 3-year DFS wihout affecting the 3-year OS. Furthermore, LVI also represents an effective indicator for adjuvant chemotherapy duration.
登录
查看更多内容
DOI：
10.1016/s1470-2045(14)70486-3
发表时间：
2014-12
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Schmoll HJ;Twelves C;Sun W;O'Connell MJ;Cartwright T;McKenna E;Saif M;Lee S;Yothers G;Haller D
通讯作者：
Haller D
影响因子：
50.5
作者：
Labianca, R.;Nordlinger, B.;Arnold, D.
通讯作者：
Arnold, D.
影响因子：
5.6
作者：
Knijn, Nikki;Mogk, Stephanie C.;Nagtegaal, Iris D.
通讯作者：
Nagtegaal, Iris D.
影响因子：
3.6
作者：
Mirkin, Katelin A.;Hollenbeak, Christopher S.;Messaris, Evangelos
通讯作者：
Messaris, Evangelos
DOI：
10.1056/nejmoa1713709
发表时间：
2018-03-29
期刊：
The New England journal of medicine
影响因子：
--
作者：
Grothey A;Sobrero AF;Shields AF;Yoshino T;Paul J;Taieb J;Souglakos J;Shi Q;Kerr R;Labianca R;Meyerhardt JA;Vernerey D;Yamanaka T;Boukovinas I;Meyers JP;Renfro LA;Niedzwiecki D;Watanabe T;Torri V;Saunders M;Sargent DJ;Andre T;Iveson T
通讯作者：
Iveson T